What stands out: Enforcement focus on mass-marketing, not patient-specific compounding Clear limits on advertising claims, including prohibitions on calling compounded products generic, the same as, or clinically proven Reinforcement of FD&C Act authorities, including misbranding provisions and Section 503A requirements Shift as shortages resolve, removing the legal basis for broad compounding of GLP-1 drugs Expanded compliance tools, including warning letters, seizure, and injunction where violations persist Bottom line: This signals a firmer FDA posture as the GLP-1 market matures, reinforcing long-standing distinctions between FDA-approved drugs and unapproved compounded preparations, particularly when promoted directly to consumers at scale
You pay the attorney for every hour worked, regardless of the outcome
The molecule gets destroyed by stomach acid without sophisticated protection
The optimal dosage range for most users falls between 20-50 mcg per day administered via subcutaneous or intramuscular injection
doi:10.1177/2042018810380215 [3] Hu D, Xie F, Xiao Y, et al
Discontinuing Glucagon-Like Peptide-1 Receptor Agonists and Body Habitus: A Systematic Review and Meta-Analysis
